- Home
- ONCO vs QNRX Comparison
ONCO vs QNRX Comparison
Compare ONCO & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | QNRX |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 9.2M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ONCO | QNRX |
|---|---|---|
| Price | $0.65 | $7.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 381.5K | ★ 901.6K |
| Earning Date | 06-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $815,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $3.25 |
| 52 Week High | $6.73 | $41.80 |
Technical Indicators
Market Signals| Indicator | ONCO | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 67.72 |
| Support Level | $0.61 | $7.00 |
| Resistance Level | $1.02 | $8.25 |
| Average True Range (ATR) | 0.09 | 0.52 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 15.73 | 76.21 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.